Costs of patients hospitalized for multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 8, 2004, Pages 1012-1016

  Rajbhandary, S S ^a   Marks, Suzanne M ^a,b   Bock, N N ^a  

^a Division of Tuberculosis Elimination   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Cost of illness; Costs and cost analysis; Multiple drug resistance; Tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LENGTH OF STAY; MALE; MORTALITY; MULTIDRUG RESISTANCE; OUTPATIENT; PHYSICIAN; PRIORITY JOURNAL; PRODUCTIVITY; SOCIETY; TUBERCULOSIS; UNITED STATES;

ADULT; COST OF ILLNESS; COSTS AND COST ANALYSIS; FEMALE; HISTORY, 18TH CENTURY; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; TUBERCULOSIS, MULTIDRUG-RESISTANT; UNITED STATES;

EID: 3543122316     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Centers for Disease Control and Prevention. Treatment of tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR 2003; 52(RR-11): 1-77.
2. Mahmoudi A, Iseman M D. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. JAMA 1993; 270: 65-68.
3. Palmer C S, Miller B, Halpern M T, Geiter L J. A model of the cost-effectiveness of directly observed therapy for treatment of tuberculosis. J Public Health Manage Pract 1998; 4: 1-13.
4. Burman W J, Dalton C B, Cohn D L, Butler J R G, Reves R R. A cost-effectiveness analysis of directly observed therapy vs. self-administered therapy for treatment of tuberculosis. Chest 1997; 112: 63-70.
5. Taylor Z, Marks S M, Rios Burrows N M, Weis S E, Stricof R L, Miller B. Causes and costs of hospitalization of tuberculosis patients in the United States. Int J Tuberc Lung Dis 2000; 4: 931-939.
6. Roberts T, Marks S. Valuation by the cost of illness method: the social costs of Escherichia coli O157:H7 foodborne disease. In: Caswell J A, ed. Valuing food safety and nutrition. Boulder, CO: Westview Press, 1992: pp 173-205.
7. Health Care Financing Administration. Provider specific cost-to-charge ratios. Washington, DC: HCFA, 1996.
8. US Bureau of the Census. Statistical Abstract of the United States. Washington, DC: US Department of Commerce, 1999 (Table 779).
9. US Bureau of Labor Statistics. Consumer Price Index B All urban consumers, Medical care. http://stats.bls.gov Accessed October 2001.
10. 2000 Physicians Fee and Coding Guide. Augusta, GA: Health-Care Consultants of America, 2001.
11. US Bureau of the Census. Statistical Abstract of the United States: 1996. 116th ed. Washington, DC: US Department of Commerce, 1996 (Tables 659, 669).
12. Haddix A C, Teutsch S M, Shaffer P A, Dunet D A. Prevention effectiveness: a guide to decision analysis and economic evaluation. New York City, NY: Oxford University Press, Inc, 1996: p 183.
13. Grosse S D. Appendix I: productivity loss tables. In: Haddix A C, Teutsch S M, Corso P S, eds. Prevention effectiveness: a guide to decision analysis and economic evaluation. 2nd ed. New York City, NY: Oxford University Press, 2003: pp 245-257.
14. Leonard M K, Larsen N, Drechsler H, et al. Increased survival of persons with tuberculosis and human immunodeficiency virus infection, 1991-2000. Clin Infect Dis 2002; 34: 1002-1007.
15. Spradling P, Moore M, McCray E, Onorato I M. Clinical out-comes in patients with multidrug-resistant tuberculosis, United States, 1993-1996. [Abstract] Am J Crit Care Med 2000; 161: A645.